Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

麗珠醫藥集團股份有限公司
LIVZON PHARMACEUTICAL GROUP INC.*
(a joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 1513)

(I) RE-ELECTION OF THE BOARD OF DIRECTORS; (II) ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR OF THE TWELFTH SESSION OF THE BOARD; (III) CHANGES IN THE COMPOSITION OF BOARD COMMITTEES; AND (IV) APPOINTMENT OF SENIOR MANAGEMENT AND SECURITIES AFFAIRS REPRESENTATIVE

(I) RE-ELECTION OF THE BOARD OF DIRECTORS

Reference is made to the circular of Livzon Pharmaceutical Group Inc.* (麗珠醫藥集團股份有限公司) (the "**Company**") dated 23 April 2025 in relation to the 2025 Annual General Meeting and the 2026 First H-Share Class Meeting (the "**Circular**"). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as defined in the Circular.

The board of directors of the Company (the "**Board**") is pleased to announce that the following matters were duly approved by the shareholders by way of ordinary resolutions at the 2025 Annual General Meeting: (i) the re-election of Mr. Zhu Baoguo (朱保國先生), Mr. Lin Nanqi (林楠棋先生) and Mr. Qiu Qingfeng (邱慶豐先生) as non-executive directors of the twelfth session of the Board; (ii) the re-election of Mr. Tang Yanggang (唐陽剛先生) and the election of Mr. Liu Daping (劉大平先生) as executive directors of the twelfth session of the Board; and (iii) the re-election of Mr. Luo Huiyuan (羅會遠先生), Ms. Cui Lijie (崔麗婕女士), Ms. Wang Zhiyao (王智瑤女士) and the election of Ms. Kang Li (康立女士) as independent non-executive directors of the twelfth session of the Board.

Biographical details of the directors of the twelfth session of the Board are set out in the Circular. The directors confirm that, as at the date of this announcement, there is no update to the biographical details as set out in the Circular that is required to be disclosed pursuant to Rule 13.51B of the Hong Kong Listing Rules. The remuneration policy for the directors is consistent with that disclosed in the Circular.

Each of Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li has separately confirmed to the Company that: (i) he/she is independent with respect to each of the factors set out in paragraphs (1) to (8) of Rule 3.13 of the Hong Kong Listing Rules; (ii) he/she has no past or present financial or other interest in the business of the Company or its subsidiaries, and is not connected with any core connected person (as defined in the Hong Kong Listing Rules) of the Company; and (iii) there is no other factor that may affect his/her independence at the time of his/her appointment or re-election.

Save as disclosed in the Circular and as at the date of this announcement, (i) none of the directors has held any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (ii) none of the directors holds any position with the Company or its subsidiaries; (iii) none of them has any relationship with any director, senior management, substantial shareholder or controlling shareholder of the Company; (iv) none of the directors has any interest in the shares of the Company or its associates within the meaning of Part XV of the Securities and Futures Ordinance; and (v) there is no other information that is required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Hong Kong Listing Rules, and there is no other matter that needs to be brought to the attention of shareholders. The Company has entered into service agreements with the above directors.

(II) ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR OF THE TWELFTH SESSION OF THE BOARD

The Board is pleased to announce that the Company held its 2026 First Employee Representative Congress (the "**Employee Representative Congress**") on 29 May 2026. Following a qualification review of the candidate by the Nomination Committee of the Board, the Employee Representative Congress elected Ms. Ran Yongmei (冉永梅女士) ("**Ms. Ran**") as the employee representative director of the twelfth session of the Board of the Company through democratic election. Upon completion of the election of the employee representative director, Ms. Ran shall form the twelfth session of the Board together with the current non-employee representative directors of the twelfth session of the Board, with a term of office commencing from the date of the Employee Representative Congress and expiring on the date when the term of the twelfth session of the Board expires. The Company has entered into a director's service agreement with Ms. Ran.

The biography of Ms. Ran is as follows:

Ms. Ran Yongmei, born in 1983, currently serves as the employee representative director of the Company. Graduated from Chongqing Medical University (重慶醫科大學) in 2006 with a Bachelor's degree in Pharmacy. Ms. Ran previously worked at Shenzhen Sanofi Pasteur Biologics Co., Ltd.* (深圳賽諾菲巴斯德生物製品有限公司), Shenzhen Salubris Pharmaceuticals Co., Ltd.* (深圳信立泰藥業股份有限公司) and Joincare Group Shenzhen Haibin Pharmaceutical Co., Ltd.* (健康元集團深圳市海濱製藥有限公司). Joined the Company in January 2022 and currently serves as Assistant to the President, concurrently holding the position of Deputy General Manager at Zhuhai Livzon MABPharm Inc.* (珠海市麗珠單抗生物技術有限公司).

Ms. Ran will receive annual director's emoluments of RMB96,000 (before tax) during her term of office. The director's emoluments have been determined with reference to her duties and responsibilities at the Company, the Company's remuneration policy and market salary benchmarks for the position.

Ms. Ran has confirmed that, save as disclosed above, (i) she has not held any directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (ii) she holds no position with the Company or its subsidiaries; (iii) she has no relationship with any director, senior management, substantial shareholder or controlling shareholder of the Company; (iv) she has no interest in the shares of the Company or its associates within the meaning of Part XV of the Securities and Futures Ordinance; and (v) there is no other information that is required to be disclosed pursuant to any of the requirements under Rules 13.51(2)(h) to (v) of the Hong Kong Listing Rules, and there is no other matter that needs to be brought to the attention of shareholders.

(III) CHANGES TO BOARD COMMITTEE COMPOSITION

The Board is pleased to announce that the first meeting of the twelfth session of the Board was held on 29 May 2026, at which the proposal on the election of members of each special committee of the twelfth session of the Board was considered and approved. The composition of the committees of the twelfth session of the Board following the adjustments is as follows:

Committee	Members
Strategy Committee	Mr. Zhu Baoguo (Chairman), Mr. Tang Yanggang, Ms. Ran Yongmei
Nomination Committee	Mr. Luo Huiyuan (Chairman), Mr. Tang Yanggang, Ms. Cui Lijie
Audit Committee	Ms. Kang Li (Chairman), Mr. Luo Huiyuan, Ms. Cui Lijie
Remuneration and Assessment Committee	Ms. Cui Lijie (Chairman), Ms. Kang Li, Mr. Tang Yanggang
Environmental, Social and Governance Committee	Mr. Zhu Baoguo (Chairman), Mr. Tang Yanggang, Ms. Kang Li, Ms. Cui Lijie, Ms. Wang Zhiyao

The terms of office of the above board committee members and chairmen shall expire on the date when the term of the twelfth session of the Board expires.

(IV) APPOINTMENT OF SENIOR MANAGEMENT AND SECURITIES AFFAIRS REPRESENTATIVE

The Board is pleased to announce that at the first meeting of the twelfth Session of the Board held on 29 May 2026, the proposals regarding the appointments of the President, Vice Presidents, Financial Controller, Secretary to the Board and Securities Affairs Representative of the Company were considered and approved. It was agreed to appoint Mr. Liu Daping (劉大平先生) ("**Mr. Liu**") as the President of the Company; to appoint Mr. Du Jun (杜軍先生) ("**Mr. Du**"), Mr. Xu Xiao (徐曉先生) ("**Mr. Xu**"), Mr. Chen Zhihua (陳志華先生) ("**Mr. Chen**") and Ms. Huang Yuxuan (黃瑜璇女士) ("**Ms. Huang**") as Vice Presidents of the Company; to appoint Mr. Wang Sheng (王勝先生) ("**Mr. Wang**") as the Financial Controller of the Company; to appoint Ms. Liu Ning (劉寧女士) ("**Ms. Liu**") as the Secretary to the Board and Company Secretary of the Company; and to appoint Ms. Xia Yu (夏雨女士) ("**Ms. Xia**") as the Securities Affairs Representative of the Company for the Shenzhen Stock Exchange.

The biographies of the above senior management and Securities Affairs Representative are set out below:

Mr. Liu Daping, born in 1987, is currently the president of the Company. Bachelor's degree from China Pharmaceutical University(中國藥科大學). Formerly served as a process engineer, workshop director, and production director at Shenzhen Haibin Pharmaceutical Co., Ltd.*(深圳市海濱製藥有限公司); executive deputy general manager at Shenzhen Taitai Pharmaceutical Co., Ltd.*(深圳太太藥業有限公司); deputy director of the production management center at Joincare Pharmaceutical Group Industry Co., Ltd.*(健康元藥業集團股份有限公司)., and general manager at Shenzhen Taitai Pharmaceutical Co., Ltd.*(深圳太太藥業有限公司). Served as Vice President of the Company from January 2024 to February 2026. As at the date of this announcement, Mr. Liu does not hold any shares in the Company.

Mr. Du Jun, born in 1977, is currently the vice president of the Company. Specialized in integrated traditional Chinese and Western medicine at Shanxi Medical University(山西醫科大學). Joined the Company in August 2011, he has served as Sales Director of the Prescription Drug Division, General Manager of the Southern Region of the Prescription Drug Division, and Assistant to the President. Currently, he holds the positions of General Manager of the Prescription Drug Division and Vice President, while also serving as a Director of the Journal of China Pharmaceutical University. As at the date of this announcement, Mr. Du does not hold any shares in the Company.

Mr. Xu Xiao, born in 1977, is currently the Vice President of the Company. Senior Pharmaceutical Engineer. Bachelor's degree from China Pharmaceutical University (中國藥科大學) and Master's degree from Peking University(北京大學). He joined Livzon Group Livzon Pharmaceutical Factory* (麗珠集團麗珠製藥廠) in July 2000, and has served successively as the Workshop Director, Technical Support Department Manager, Production Technology Director, Executive Deputy Factory Director, and Assistant to the President of Livzon Group. He currently serves as the Director of Livzon Group Livzon Pharmaceutical Factory and the Dean of Livzon Group Research Institute. As at the date of this announcement, Mr. Xu does not hold any shares in the Company.

Ms. Huang Yuxuan, born in 1966, is currently the vice president of the Company. Bachelor's degree from Fujian Agriculture and Forestry University(福建農林大學), completed postgraduate courses in business management at the University of International Business and Economics(對外經濟貿易大學), and holds the title of Senior Economist. Joined the Group in 2005 and served as Deputy General Manager of Fuzhou Fuxing, Deputy General Manager of the API Division, General Manager of Zhuhai Livzon Pharmaceutical Trading Co., Ltd.*(珠海市麗珠醫藥貿易有限公司) , and Assistant to the President of the Group. He has served as Vice President of the Company since October 2018 and currently holds a concurrent position as Director of Fujian Kunhe Investment Co., Ltd.*(福建坤禾投資有限公司). As at the date of this announcement, Ms. Huang does not hold any shares in the Company.

Mr. Wang Sheng, born in 1982, currently serves as the Chief Financial Officer of the Company. Bachelor's degree from the University of Science and Technology of China(中國科學技術大學); completed the Advanced Tax Director Program at Shanghai University of Finance and Economics(上海財經大學) and earned the Senior Tax Planner qualification. Member of the Chartered Institute of Management Accountants (CIMA), holding professional qualifications as a Certified Public Accountant in Australia, Global Chartered Management Accountant, and Certified Tax Agent in China. Formerly served as Tax Manager and Consultant at Deloitte(德勤會計師事務所), and as Financial Head for the Hong Kong Region and Tax Head for Greater China and North Asia at Takeda Pharmaceutical Group(武田製藥集團). Joined the Company in September 2025 as Chief Financial Officer. As at the date of this announcement, Mr. Wang does not hold any shares of the Company.

Mr. Chen Zhihua, born in 1981, currently serves as Vice President of the Company. Graduated with a Bachelor's degree in Business Administration from Beijing Jiaotong University(北京交通大學). Formerly served as a sales representative and regional manager at Jiangsu Hansoh Medicine* (江蘇豪森藥業), and as the northern region sales director at Chengdu Yuandong Biopharmaceutical* (成都苑東生物製藥). Joined the Company in March 2021 and has held the positions of general manager of the Beijing provincial company in the prescription drug division, general manager of the North China region in the prescription drug division, and assistant to the president. Currently serves as the Company's vice president, deputy general manager of the prescription drug division, and general manager of the northern region in the prescription drug division. As at the date of this announcement, Mr. Chen does not hold any shares of the Company.

Ms. Liu Ning, born in 1983, is currently the Secretary to the Board, the Company Secretary and the Authorised Representative of the Company. Bachelor of Laws. Holds qualifications as a Certified Public Accountant in China, a Legal Professional Qualification in China, and a member of Association of Chartered Certified Accountant in the United Kingdom. Formerly worked in the investment banking department of a securities Company and a private equity investment fund, specializing in domestic and international investment and financing, mergers and acquisitions, and compliance consulting for listed companies. Former Deputy General Manager of Zhuhai Livzon Diagnostics Inc(珠海麗珠試劑股份有限公司). From January 2021 to present, she has been an independent director of Telink Semiconductor (Shanghai) Co., Ltd.*（泰凌微電子（上海）股份有限公司）(688591.SH). As at the date of this announcement, Ms. Liu does not hold any shares of the Company.

Ms. Xia Yu, born in 1996. She holds a Master's degree, having obtained both her Bachelor's and Master's degrees from China University of Political Science and Law (中國政法大學). She has been employed in the Board Secretariat of the Company since July 2025. As at the date of this announcement, Ms. Xia does not hold any shares of the Company.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
29 May 2026

As at the date of this announcement, the executive directors of the Company are Mr. Liu Daping (President) and Mr. Tang Yanggang (Vice Chairman); the non-executive directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the employee representative director of the Company is Ms. Ran Yongmei; and the independent non-executive directors of the Company are Mr. Luo Huiyuan, Ms. Cui Lijie, Ms. Wang Zhiyao and Ms. Kang Li.

* *For identification purpose only*